Your session is about to expire
← Back to Search
Contrast ultrasound arm for Liver Cancer
Phase 3
Waitlist Available
Led By John Eisenbrey, PhD
Research Sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients >= 21 years of age
Patient capable of making informed decisions regarding his/her treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure
Awards & highlights
Study Summary
This study is evaluating whether ultrasound may be used to monitor the effectiveness of a treatment for liver cancer.
Eligible Conditions
- Liver Cancer
- Chemoembolization
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization
Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization
Trial Design
1Treatment groups
Experimental Treatment
Group I: Contrast ultrasound armExperimental Treatment2 Interventions
Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perflutren
FDA approved
Logiq E9 Scanner (Contrast-enhanced ultrasound)
2016
Completed Phase 3
~140
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,927,210 Total Patients Enrolled
104 Trials studying Liver Cancer
26,668 Patients Enrolled for Liver Cancer
Lantheus Medical ImagingIndustry Sponsor
55 Previous Clinical Trials
4,332,528 Total Patients Enrolled
GE HealthcareIndustry Sponsor
288 Previous Clinical Trials
630,895 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger